Previous Close | 0.9400 |
Open | 0.9776 |
Bid | 0.9701 x 1200 |
Ask | 0.9999 x 39400 |
Day's Range | 0.9601 - 1.0500 |
52 Week Range | 0.5500 - 2.4000 |
Volume | |
Avg. Volume | 543,193 |
Market Cap | 47.568M |
Beta (5Y Monthly) | -0.59 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4040 |
Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.83 |
Subscribe to Yahoo Finance Plus to view Fair Value for AIM
OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer of AIM, will present at the H.C. Wainwright Global Investment Conference being held May 23-26,
AIM Chief Medical Officer David Strayer, MD AIM Chief Medical Officer David Strayer, MD Charles Lapp, MD, Principal Investigator for AMP-511 at Hunter-Hopkins Center in Charlotte, N.C. Charles Lapp, MD, Principal Investigator for AMP-511 at Hunter-Hopkins Center in Charlotte, N.C. Oved Amitay, President and CEO of the advocacy organization Solve M.E. Oved Amitay, President and CEO of the advocacy organization Solve M.E. AIM CEO Thomas K. Equels AIM CEO Thomas K. Equels OCALA, Fla., May 18, 2022
- First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continued positive data in ovarian and triple-negative breast cancer clinical studies as well as clinical potential with checkpoint inhibitors - On track to commence Phase 2 study for lead program of Ampligen for pancreatic cancer Q3 2022 - Focus on further advancement of oncology pipeline and well-positio